Basecamp Research, an AI company focused on solving the most pressing challenges in life sciences, today announced that it has closed $60 million in Series B funding led by Singular, bringing its total raised to date to $85 million.
Basecamp Research builds foundational AI models on the world’s largest ethically sourced database of biological information, giving AI the most complete understanding of biology ever.
This allows the company to design complex biological systems whose performance improves dramatically as the AI recognizes more diversity and context.
Basecamp Research works with biopharmaceutical companies and academic research institutions to design new protein sequences and biological systems that can transform therapeutic research and development.
Our team of explorers, scientists, and policy experts proudly collaborate with over 100 biodiversity partners around the world to discover breakthroughs that can have a profound impact on healthcare and patient lives. We can provide long-term results.
The company also has a multi-year collaboration with the lab of Dr. David R Liu at the Broad Institute of MIT and Harvard University. Dr. Liu is a Howard Hughes Medical Institute Investigator and a core member of the Broad.
Basecamp Research and Liu Lab’s collaboration promises to advance new approaches to programmable genetic medicines that have the potential to transform treatments for a wide range of diseases.
“By focusing on solving fundamental data gaps facing the entire biotech industry, we are pushing the limits of AI in biological design,” said Dr. Glenn Gowers, co-founder and CEO of Basecamp Research. It exceeds that.”
“Basecamp Research uses our technology to generate new and deep insights beyond known biology, expanding what we can offer to our partners in the biopharmaceutical ecosystem every day.”
Basecamp Research is collaborating with Dr. Liu’s lab to pioneer the development of new fusion proteins and other macromolecules that will enable the next generation of genetic medicines.
Dr Gowers said:
“Our collaboration combines Liu Lab’s pioneering research in genome editing and cutting-edge wet lab development expertise with Basecamp Research’s unique datasets collected from around the world and beyond the limits of human-based design. combined with an in-house AI model designed to
Basecamp Research’s funding was led by Singular, with additional investors including S32, redalpine, Roche vice chairman André Hoffmann, Royal Philips chairman and former DSM CEO Feike Sijbesma, and former Unilever CEO Paul Polman. Returning investors participating in the Series B include True Ventures and Hummingbird Ventures.
The Series B proceeds will be used to expand the pace and volume of Basecamp Research’s data collection, with fundamental data already containing 100 times more sophisticated biological systems than the public databases most commonly used by pharmaceutical researchers. Expand the set.
This funding round follows 15 successful commercial bioscience partnerships across a wide range of industries. Raffi Kamber, general partner at Singular, said:
“The team at Basecamp Research is building powerful AI models that truly understand the breadth and complexity of biology.
Their knowledge graph will drive a step change in the performance of AI-based designs and fundamentally change the way life sciences teams innovate. We’re excited to support visionary companies and teams that are reshaping entire industries. ”
Dr. Oliver Vince, co-founder of Basecamp Research, added:
“We have used AI to solve a wide range of difficult problems in bioscience, and we look forward to continuing to work with our partners on groundbreaking projects.
We are excited about this momentum and look forward to continuing to push the limits of biology as we know it today. ”
Lead image: Glen Gowers and Oliver Vince, co-founders of Basecamp Research. Photo: No credit.
